Theriva Biologics, Inc. TOVX
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company's acquisition of Theriva Biologics, S.L. ("VCN", formerly named VCN Biosciences, S.L.), in March 2022, as described in more detail below (the "Acquisition"), we transitioned our strategic focus to oncology through the development of VCN's new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient's immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer ("VIRAGE"), and a Phase 1 clinical study for the treatment of retinoblastoma, as well as various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $8.6M | $12.0M | $14.3M | $11.7M | $7.8M | $5.1M | $11.1M | $11.8M | $18.8M | $29.1M |
| SG&A | $15.4M | $7.4M | $7.1M | $9.9M | $6.5M | $5.0M | $4.6M | $5.7M | $7.5M | $10.1M |
| Total operating expenses | $24.1M | $26.3M | $21.4M | $21.6M | $14.3M | $10.2M | $15.7M | $17.6M | $26.3M | $39.3M |
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M | -$14.3M | -$10.2M | -$15.7M | -$17.6M | -$26.3M | -$39.3M |
| Pre-tax income | -$23.7M | -$25.7M | -$20.0M | -$21.1M | -$14.3M | -$10.0M | -$15.3M | -$13.4M | -$15.2M | -$27.3M |
| Income tax | — | $0 | $1.6M | $1.4M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$23.7M | -$25.7M | -$18.3M | -$19.7M | -$14.3M | -$10.0M | -$15.3M | -$13.4M | -$15.2M | -$27.3M |
| EPS, basic | -2.08 | -19.03 | -28.48 | -1.31 | -1.90 | -0.66 | — | — | — | — |
| EPS, diluted | -2.08 | -19.03 | -28.48 | -1.31 | -1.90 | -0.66 | -0.98 | -4.06 | -6.23 | -0.29 |
| Shares, diluted (wtd. avg.) | 12.1M | 1.3M | 644,282 | 15.3M | 12.2M | 19.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.1M | $11.6M | $23.3M | $41.9M | $67.3M | $6.2M | $15.0M | $28.9M | $17.1M | $19.1M |
| Total current assets | $17.5M | $16.3M | $27.4M | $45.5M | $68.9M | $7.9M | $16.4M | $29.5M | $17.9M | $21.6M |
| Property, plant and equipment | $222.0K | $270.0K | $422.0K | $345.0K | $101.0K | $174.0K | $367.0K | $607.0K | $872.0K | $905.0K |
| Goodwill | — | $0 | $5.7M | $5.5M | — | — | — | — | — | — |
| Other intangibles | $19.6M | $17.4M | $19.8M | $19.1M | — | — | — | — | — | — |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $70.4M | $8.4M | $17.2M | $30.1M | $18.8M | $22.5M |
| Accounts payable | $1.0M | $859.0K | $770.0K | $915.0K | $524.0K | $886.0K | $2.3M | $1.0M | $2.0M | $2.0M |
| Short-term debt | — | — | $63.0K | $57.0K | — | — | — | — | — | — |
| Total current liabilities | $10.0M | $7.6M | $6.7M | $7.1M | $3.6M | $3.0M | $5.3M | $3.4M | $9.8M | $19.8M |
| Long-term debt | $1.7M | $92.0K | $162.0K | $221.0K | — | — | — | — | — | — |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $5.0M | $3.2M | $5.7M | $3.7M | $10.2M | $20.2M |
| Retained earnings | -$358.7M | -$335.0M | -$309.3M | -$291.0M | -$271.3M | -$248.1M | -$235.5M | -$219.5M | -$194.2M | -$172.0M |
| Total equity | $15.4M | $19.1M | $37.0M | $51.8M | $65.4M | -$7.5M | -$1.1M | $14.2M | -$3.4M | $2.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.7M | -$16.9M | -$19.0M | -$19.1M | -$12.9M | -$12.2M | -$13.9M | -$17.3M | -$20.2M | -$27.9M |
| Depreciation and amortisation | $108.0K | $137.0K | $135.0K | $85.0K | $87.0K | $201.0K | $240.0K | $272.0K | $245.0K | $157.0K |
| Stock-based compensation | $654.0K | $671.0K | $552.0K | $475.0K | $416.0K | $350.0K | $340.0K | $2.1M | $3.4M | $4.0M |
| Capital expenditure | $35.0K | $1.0K | $202.0K | $116.0K | $14.0K | $9.0K | $0 | $7.0K | $212.0K | $569.0K |
| Investing cash flow | -$35.0K | -$1.0K | -$202.0K | -$4.4M | -$14.0K | -$9.0K | $0 | -$7.0K | -$212.0K | -$569.0K |
| Financing cash flow | $18.2M | $5.5M | $625.0K | -$1.9M | $74.0M | $3.4M | $0 | $29.1M | $18.5M | $26.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-078859.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$27.3M | -$15.2M | -$13.4M | -$15.3M | -$10.0M | -$14.3M | -$19.7M | -$18.3M | -$25.7M | -$23.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |